Overview

Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma

Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Oncoxin in combination with Surafenib is safe and results in improved survival in patients with hepatocellular carcinoma (HCC)
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Clinical Research Organization, Dhaka, Bangladesh
Treatments:
Sorafenib